The objective of this proposal is to conduct a prospective randomized study comparing the
utility of sedating patients undergoing transesophageal echocardiographic studies with a
novel, recently-FDA-approved sedative agent, remimazolam, versus the sedative used in our
current practice at UAB, propofol. This study will investigate whether remimazolam offers any
benefit over current care vis-à-vis hemodynamics or efficiency/throughput.
This study will be conducted at the University of Alabama at Birmingham. All outpatients and
inpatients scheduled for elective/non-emergent TEE in the UAB Heart and Vascular Center TEE
lab will be considered for enrollment.